Search

Your search keyword '"Buchler M"' showing total 16 results
Start Over Author "Buchler M" Language undetermined
16 results on '"Buchler M"'

1. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer

Author

Kelly M. E., Glynn R., Aalbers A. G. J., Abraham-Nordling M., Alberda W., Antoniou A., Austin K. K., Beets G. L., Beynon J., Bosman S. J., Brunner M., Buchler M. W., Burger J. W. A., Campain N., Christensen H. K., Codd M., Coscia M., Colquhoun A. J., Daniels I. R., Davies R. J., de Wilt J. H. W., Deutsch C., Dietz D., Eglinton T., Fearnhead N., Frizelle F. A., Garcia-Sabrido J. L., George M. L., Gentilini L., Harris D. A., Harji D., Heriot A. G., Hohenberger Brunner W., Jenkins J. T., Kanemitsu Y., Chan K. K. L., Kim H., Koh C. E., Kok N. F., Kontovounisios C., Kulu Y., Law W. L., Le G. N., Lee P., Lydrup M. L., Lynch A. C., Martling A., Meijerink J., Merkel S., McDermott F. D., McGrath J. S., Nielsen Christensen M. B., Nieuwenhuijzen G. A. P., Nordling M. A., Northover J. M. A., O'Connell P. R., Patsouras D., Poggioli G., Radwan R. W., Rasheed S., Rasmussen P. C., Rothbarth J., Rutten H. J. T., Sagar P. M., Schizas A. M. P., Shida D., Smart N. J., Solomon M. J., Stocchi L., Tekkis P. P., Tsukamoto S., Turner W. H., Tuynman J., Ulrich A., van Leeuwenhoek A., van Ramshorst G. H., Vasquez-Jimenez W., Verhoef C., Versteegen M., Wakeman C., Warrier S., Yip J., Winter D. C., Surgery, Kelly M.E., Glynn R., Aalbers A.G.J., Abraham-Nordling M., Alberda W., Antoniou A., Austin K.K., Beets G.L., Beynon J., Bosman S.J., Brunner M., Buchler M.W., Burger J.W.A., Campain N., Christensen H.K., Codd M., Coscia M., Colquhoun A.J., Daniels I.R., Davies R.J., de Wilt J.H.W., Deutsch C., Dietz D., Eglinton T., Fearnhead N., Frizelle F.A., Garcia-Sabrido J.L., George M.L., Gentilini L., Harris D.A., Harji D., Heriot A.G., Hohenberger Brunner W., Jenkins J.T., Kanemitsu Y., Chan K.K.L., Kim H., Koh C.E., Kok N.F., Kontovounisios C., Kulu Y., Law W.L., Le G.N., Lee P., Lydrup M.L., Lynch A.C., Martling A., Meijerink J., Merkel S., McDermott F.D., McGrath J.S., Nielsen Christensen M.B., Nieuwenhuijzen G.A.P., Nordling M.A., Northover J.M.A., O'Connell P.R., Patsouras D., Poggioli G., Radwan R.W., Rasheed S., Rasmussen P.C., Rothbarth J., Rutten H.J.T., Sagar P.M., Schizas A.M.P., Shida D., Smart N.J., Solomon M.J., Stocchi L., Tekkis P.P., Tsukamoto S., Turner W.H., Tuynman J., Ulrich A., van Leeuwenhoek A., van Ramshorst G.H., Vasquez-Jimenez W., Verhoef C., Versteegen M., Wakeman C., Warrier S., Yip J., Winter D.C., AGEM - Re-generation and cancer of the digestive system, and CCA - Cancer Treatment and quality of life

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, 030230 surgery, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, medicine, Clinical endpoint, Humans, Survival rate, Survival analysis, Neoadjuvant therapy, Aged, Rectal Neoplasm, Pelvic exenteration, Rectal Neoplasms, business.industry, Odds ratio, Middle Aged, Survival Analysis, Neoadjuvant Therapy, Pelvic Exenteration, Surgery, Radiation therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Resection margin, Female, Survival Analysi, Neoplasm Recurrence, Local, business, Human
Abstract

Background Pelvic exenteration for locally recurrent rectal cancer (LRRC) is associated with variable outcomes, with the majority of data from single-centre series. This study analysed data from an international collaboration to determine robust parameters that could inform clinical decision-making. Methods Anonymized data on patients who had pelvic exenteration for LRRC between 2004 and 2014 were accrued from 27 specialist centres. The primary endpoint was survival. The impact of resection margin, bone resection, node status and use of neoadjuvant therapy (before exenteration) was assessed. Results Of 1184 patients, 614 (51·9 per cent) had neoadjuvant therapy. A clear resection margin (R0 resection) was achieved in 55·4 per cent of operations. Twenty-one patients (1·8 per cent) died within 30 days and 380 (32·1 per cent) experienced a major complication. Median overall survival was 36 months following R0 resection, 27 months after R1 resection and 16 months following R2 resection (P < 0·001). Patients who received neoadjuvant therapy had more postoperative complications (unadjusted odds ratio (OR) 1·53), readmissions (unadjusted OR 2·33) and radiological reinterventions (unadjusted OR 2·12). Three-year survival rates were 48·1 per cent, 33·9 per cent and 15 per cent respectively. Bone resection (when required) was associated with a longer median survival (36 versus 29 months; P < 0·001). Node-positive patients had a shorter median overall survival than those with node-negative disease (22 versus 29 months respectively). Multivariable analysis identified margin status and bone resection as significant determinants of long-term survival. Conclusion Negative margins and bone resection (where needed) were identified as the most important factors influencing overall survival. Neoadjuvant therapy before pelvic exenteration did not affect survival, but was associated with higher rates of readmission, complications and radiological reintervention.

Published
2018

2. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies

Author

Glotz, D., Russ, G., Rostaing, L., Legendre, C., Tufveson, G., Chadban, S., Grinyo, J., Mamode, N., Rigotti, P., Couzi, L., Buchler, M., Sandrini, S., Dain, B., Garfield, Malcolm, Ogawa, M., Richard, T., Marks, W. H., Merville, P., Lebranchu, Y., Mjornstedt, L., Hughes, P., Torpey, N., and Kamar, N.

Subjects
Graft Rejection, Male, donors and donation, kidney transplantation/nephrology, 030230 surgery, sensitization, complement biology, clinical research/practice, donors and donation: deceased, immunosuppressant-fusion proteins and monoclonal antibodies, rejection: antibody-mediated (ABMR), 0302 clinical medicine, Isoantibodies, Risk Factors, deceased, Immunology and Allergy, Medicine, Pharmacology (medical), Kidney transplantation, biology, Graft Survival, Eculizumab, Middle Aged, Prognosis, practice, Tissue Donors, Survival Rate, Monoclonal, Female, Patient Safety, rejection, Antibody, medicine.drug, Adult, Adolescent, nephrology, kidney transplantation, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, antibody-mediated (ABMR), Humans, In patient, Survival rate, Aged, Transplantation, business.industry, Kirurgi, medicine.disease, Kidney Transplantation, Complement Inactivating Agents, clinical research, Immunology, biology.protein, Kidney Failure, Chronic, Surgery, business, Follow-Up Studies
Abstract

The presence of preformed donor-specific antibodies in transplant recipients increases the risk of acute antibody-mediated rejection (AMR). Results of an open-label single-arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies are reported. Participants received eculizumab as follows: 1200 mg immediately before reperfusion; 900 mg on posttransplant days 1, 7, 14, 21, and 28; and 1200 mg at weeks 5, 7, and 9. All patients received thymoglobulin induction therapy and standard maintenance immunosuppression including steroids. The primary end point was treatment failure rate, a composite of biopsy-proved grade II/III AMR (Banff 2007 criteria), graft loss, death, or loss to follow-up, within 9 weeks posttransplant. Eighty patients received transplants (48 women); the median age was 52 years (range 24-70 years). Observed treatment failure rate (8.8%) was significantly lower than expected for standard care (40%; P < .001). By 9 weeks, 3 of 80 patients had experienced AMR, and 4 of 80 had experienced graft loss. At 36 months, graft and patient survival rates were 83.4% and 91.5%, respectively. Eculizumab was well tolerated and no new safety concerns were identified. Eculizumab has the potential to provide prophylaxis against injury caused by acute AMR in such patients (EudraCT 2010-019631-35).

Published
2018

3. Search for the flavor-changing neutral current decay D0→μ+μ− with the HERA-B detector

Author

Abt, I., Adams, M., Albrecht, H., Aleksandrov, A., Amaral, V., Amorim, A., Aplin, S.J., Aushev, V., Bagaturia, Y., Balagura, V., Bargiotti, M., Barsukova, O., Bastos, J., Batista, J., Bauer, C., Bauer, Th.S., Belkov, A., Belkov, Ar., Belotelov, I., Bertin, A., Bobchenko, B., Böcker, M., Bogatyrev, A., Bohm, G., Bräuer, M., Bruinsma, M., Bruschi, M., Buchholz, P., Buchler, M., Buran, T., Carvalho, J., Conde, P., Cruse, C., Dam, M., Danielsen, K.M., Danilov, M., De Castro, S., Deppe, H., Dong, X., Dreis, H.B., Egorytchev, V., Ehret, K., Eisele, F., Emeliyanov, D., Essenov, S., Fabbri, L., Faccioli, P., Feuerstack-Raible, M., Flammer, J., Fominykh, B., Funcke, M., Garrido, Ll., Giacobbe, B., Gläß, J., Goloubkov, D., Golubkov, Y., Golutvin, A., Golutvin, I., Gorbounov, I., Gorišek, A., Gouchtchine, O., Goulart, D.C., Gradl, S., Gradl, W., Grimaldi, F., Guilitsky, Yu., Hansen, J.D., Harr, R., Hernández, J.M., Hofmann, W., Hott, T., Hulsbergen, W., Husemann, U., Igonkina, O., Ispiryan, M., Jagla, T., Jiang, C., Kapitza, H., Karabekyan, S., Karchin, P., Karpenko, N., Keller, S., Kessler, J., Khasanov, F., Kiryushin, Yu., Knöpfle, K.T., Kolanoski, H., Korpar, S., Krauss, C., Kreuzer, P., Križan, P., Krücker, D., Kupper, S., Kvaratskheliia, T., Lanyov, A., Lau, K., Lewendel, B., Lohse, T., Lomonosov, B., Männer, R., Masciocchi, S., Massa, I., Matchikhilian, I., Medin, G., Medinnis, M., Mevius, M., Michetti, A., Mikhailov, Yu., Mizuk, R., Muresan, R., Nam, S., zur Nedden, M., Negodaev, M., Nörenberg, M., Nowak, S., Núñez Pardo de Vera, M.T., Ouchrif, M., Ould-Saada, F., Padilla, C., Peralta, D., Pernack, R., Pestotnik, R., Piccinini, M., Pleier, M.A., Poli, M., Popov, V., Pose, A., Pose, D., Prystupa, S., Pugatch, V., Pylypchenko, Y., Pyrlik, J., Reeves, K., Reßing, D., Rick, H., Riu, I., Robmann, P., Rybnikov, V., Sánchez, F., Sbrizzi, A., Schmelling, M., Schmidt, B., Schreiner, A., Schröder, H., Schwartz, A.J., Schwarz, A.S., Schwenninger, B., Schwingenheuer, B., Sciacca, F., Semprini-Cesari, N., Shiu, J., Shuvalov, S., Silva, L., Smirnov, K., Sözüer, L., Solunin, S., Somov, A., Somov, S., Spengler, J., Spighi, R., Spiridonov, A., Stanovnik, A., Starič, M., Stegmann, C., Subramania, H.S., Symalla, M., Tikhomirov, I., Titov, M., Tsakov, I., Uwer, U., van Eldik, C., Vassiliev, Yu., Villa, M., Vitale, A., Vukotic, I., Wahlberg, H., Walenta, A.H., Walter, M., Wang, J.J., Wegener, D., Werthenbach, U., Wolters, H., Wurth, R., Wurz, A., Zaitsev, Yu., Zavertyaev, M., Zeuner, T., Zhelezov, A., Zheng, Z., Zimmermann, R., Živko, T., and Zoccoli, A.

Subjects
Nuclear and High Energy Physics
Published
2004
Full Text
View/download PDF

4. A gaseous muon detector at the HERA-B experiment

Author

Danilov, M., Eiges, V., Fominykh, B., Gilitsky, Yu, Khasanov, F., Kvaratscheliia, T., Laptin, L., Tchoudakov, V., Tichomirov, I., Maxim Titov, Zaitsev, Yu, Buchler, M., Harr, R. F., Karchin, P. E., Nam, S., Shiu, J. G., and Takach, S. F.

Published
2002

5. Dispersive Treatment of K --> Pi Pi

Author

Buchler, M.

Subjects
High Energy Physics - Phenomenology (hep-ph), FOS: Physical sciences
Abstract

We propose a new method to obtain the K -> pi pi amplitude from K -> pi which allows one to fully account for the effects of final state interactions. The method is based on a set of dispersion relations for the K -> pi pi amplitude in which the weak Hamiltonian carries momentum. The soft pion theorem, which relates this amplitude to the K -> pi amplitude, can be used to determine one of the two subtraction constants - the second constant is at present known only to leading order in chiral perturbation theory., Latex, 4 pages, 1 figure

Published
2002
Full Text
View/download PDF

6. Inclusive V0 production cross sections from 920 GeV fixed target proton-nucleus collisions: The HERA-B Collaboration

Author

Abt, I., Abyzov, A., Adams, M., Albrecht, H., Amaral, V., Amorim, A., Aplin, S. J., Arefiev, A., Ariño, I., Atiya, M., Aushev, V., Bagaturia, Y., Baghshetsyan, R., Balagura, V., Bargiotti, M., Barsuk, S., Barsukova, O., Bassetti, V., Bastos, J., Bauer, C., Bauer, T. S., Beck, M., Belkov, A., Belotelov, I., Belyaev, I., Berkhan, K., Bertin, A., Bobchenko, B., Böcker, M., Bogatyrev, A., Bohm, G., Borgmeier, C., Bräuer, M., Broemmelsiek, D., Bruinsma, M., Bruschi, M., Buchholz, P., Buchler, M., Buran, T., Capeáns, M., Capponi, M., Carvalho, J., Chamanina, J., Chen, B. X., Chistov, R., Chmeissani, M., Christensen, A., Conde, P., Cruse, C., Dam, M., Danielsen, K. M., Danilov, M., Castro, S., Deckers, H., Dehmelt, K., Deppe, H., Dolgoshein, B., Dong, X., Dreis, H. B., Dressel, M., Dujmic, D., Eckmann, R., Egorytchev, V., Ehret, K., Eiges, V., Eisele, F., Emeliyanov, D., Erhan, S., Essenov, S., Fabbri, L., Faccioli, P., Fallot-Burghardt, W., Feuerstack-Raible, M., Flammer, J., Fleckenstein, H., Fominykh, B., Fourletov, S., Fuljahn, T., Funcke, M., Galli, D., Garcia, A., Garrido, L., Gascon, D., Gellrich, A., Gerndt, K. E. K., Giacobbe, B., Gläs, J., Glebe, T., Goloubkov, D., Golutvin, A., Golutvin, I., Gorbounov, I., Gorišek, A., Gouchtchine, O., Goulart, D. C., Gradl, S., Gradl, W., Guilitsky, Y., Hamacher, T., Hansen, J. D., Harr, R., Hast, C., Hausmann, S., Hernández, J. M., Hildebrandt, M., Hölscher, A., Höpfner, K., Hofmann, W., Hohlmann, M., Hott, T., Hulsbergen, W., Husemann, U., Igonkina, O., Ispiryan, M., Işsever, S., Itterbeck, H., Ivarsson, J., Jagla, T., Jia, Y., Jiang, C., Kaoukher, A., Kapitza, H., Karabekyan, S., Karchin, P., Karpenko, N., Ke, Z., Keller, S., Khasanov, F., Kim, H., Kiryushin, Y., Kisel, I., Klefenz, F., Knöpfle, K. T., Kochetkov, V., Kolanoski, H., Korpar, S., Krauss, C., Kreuzer, P., Križan, P., Krücker, D., Kvaratskheliia, T., Lange, A., Lanyov, A., Lau, K., Leffers, G., Legrand, I., Lewendel, B., Liu, Y. Q., Lohse, T., Loke, R., Lomonosov, B., Lödemann, J., Männer, R., Mankel, R., Marconi, U., Masciocchi, S., Massa, I., Matchikhilian, I., Medin, G., Medinnis, M., Mevius, M., Michetti, A., Mikhailov, Yu, Miquel, R., Mizuk, R., Mohapatra, A., Moshkin, A., Moshous, B., Muresan, R., Nam, S., Negodaev, M., Négri, I., Nörenberg, M., Nowak, S., Núñez Pardo Vera, M. T., Oest, T., Oliveira, A., Ouchrif, M., Ould-Saada, F., Padilla, C., Pakhlov, P., Pavlenko, Yu, Peralta, D., Pernack, R., Perschke, T., Pestotnik, R., Petersen, B. Aa, Piccinini, M., Pleier, M. A., Poli, M., Popov, V., Pose, A., Pose, D., Potashnikova, I., Pugatch, V., Pylypchenko, Y., Pyrlik, J., Ramachandran, S., Ratnikov, F., Reeves, K., Rebing, D., Riechmann, K., Rieling, J., Rietz, M., Riu, I., Robmann, P., Rosen, J., Rothe, Ch, Ruckstuhl, W., Rusinov, V., Rybnikov, V., Ryzhikov, D., Saadi-Lüdemann, F., Samtleben, D., Sánchez, F., Sang, M., Saveliev, V., Sbrizzi, A., Schaller, S., Schlein, P., Schmelling, M., Schmidt, B., Schmidt, S., Schmidt-Parzefall, W., Schreiner, A., Schröder, H., Schultz, H. D., Schwanke, U., Schwartz, A. J., Schwarz, A. S., Schwenninger, B., Schwingenheuer, B., Schwitters, R., Sciacca, F., Semenov, S., Semprini-Cesari, N., Sexauer, E., Seybold, L., Shiu, J., Shuvalov, S., Siccama, I., Škrk, D., Sözüer, L., Soldatov, A., Solunin, S., Somov, A., Somov, S., Souvorov, V., Spahn, M., Spengler, J., Spighi, R., Spiridonov, A., Spratte, S., Stanovnik, A., Starič, M., Stdenis, R., Stegmann, C., Steinbeck, S., Steinkamp, O., Stieler, D., Straumann, U., Sun, F., Sun, H., Symalla, M., Takach, S., Tesch, N., Thurn, H., Tikhomirov, I., Titov, M., Trunk, U., Truöl, P., Tsakov, I., Uwer, U., Vincenzo Maria Vagnoni, Eldik, C., Staa, R., Vassiliev, Yu, Villa, M., Vitale, A., Vukotic, I., Wagner, G., Wagner, W., Wahlberg, H., Walenta, A. H., Walter, M., Walter, T., Wang, J. J., Wang, Y. M., Wanke, R., Wegener, D., Werthenbach, U., Weyers, P. J., Wolters, H., Wurth, R., Wurz, A., Xella-Hansen, S., Yang, J., Zaitsev, Yu, Zavertyaev, M., Zech, G., Zeuner, T., Zhelezov, A., Zheng, Z., Zhu, Z., Zimmermann, R., Živko, T., Zoccoli, A., and Zweizig, J.

8. Inclusive V0 production cross sections from 920 GeV fixed target proton-nucleus collisions: The HERA-B Collaboration

Author

Abt, I., Abyzov, A., Adams, M., Albrecht, H., Amaral, V., Amorim, A., Aplin, S. J., Arefiev, A., Ariño, I., Atiya, M., Aushev, V., Bagaturia, Y., Baghshetsyan, R., Balagura, V., Bargiotti, M., Barsuk, S., Barsukova, O., Bassetti, V., Bastos, J., Bauer, C., Bauer, T. S., Beck, M., Belkov, A., Belotelov, I., Belyaev, I., Berkhan, K., Bertin, A., Bobchenko, B., Böcker, M., Bogatyrev, A., Bohm, G., Borgmeier, C., Bräuer, M., Broemmelsiek, D., Bruinsma, M., Bruschi, M., Buchholz, P., Buchler, M., Buran, T., Capeáns, M., Capponi, M., Carvalho, J., Chamanina, J., Chen, B. X., Chistov, R., Chmeissani, M., Christensen, A., Conde, P., Cruse, C., Dam, M., Danielsen, K. M., Danilov, M., Castro, S., Deckers, H., Dehmelt, K., Deppe, H., Dolgoshein, B., Dong, X., Dreis, H. B., Dressel, M., Dujmic, D., Eckmann, R., Egorytchev, V., Ehret, K., Eiges, V., Eisele, F., Emeliyanov, D., Erhan, S., Essenov, S., Fabbri, L., Faccioli, P., Fallot-Burghardt, W., Feuerstack-Raible, M., Flammer, J., Fleckenstein, H., Fominykh, B., Fourletov, S., Fuljahn, T., Funcke, M., Galli, D., Garcia, A., Garrido, L., Gascon, D., Gellrich, A., Gerndt, K. E. K., Giacobbe, B., Gläs, J., Glebe, T., Goloubkov, D., Golutvin, A., Golutvin, I., Gorbounov, I., Gorišek, A., Gouchtchine, O., Goulart, D. C., Gradl, S., Gradl, W., Guilitsky, Y., Hamacher, T., Hansen, J. D., Harr, R., Hast, C., Hausmann, S., Hernández, J. M., Hildebrandt, M., Hölscher, A., Höpfner, K., Hofmann, W., Hohlmann, M., Hott, T., Hulsbergen, W., Husemann, U., Igonkina, O., Ispiryan, M., Işsever, S., Itterbeck, H., Ivarsson, J., Jagla, T., Jia, Y., Jiang, C., Kaoukher, A., Kapitza, H., Karabekyan, S., Karchin, P., Karpenko, N., Ke, Z., Keller, S., Khasanov, F., Kim, H., Kiryushin, Y., Kisel, I., Klefenz, F., Knöpfle, K. T., Kochetkov, V., Kolanoski, H., Korpar, S., Krauss, C., Kreuzer, P., Križan, P., Krücker, D., Kvaratskheliia, T., Lange, A., Lanyov, A., Lau, K., Leffers, G., Legrand, I., Lewendel, B., Liu, Y. Q., Lohse, T., Loke, R., Lomonosov, B., Lödemann, J., Männer, R., Mankel, R., Marconi, U., Masciocchi, S., Massa, I., Matchikhilian, I., Medin, G., Medinnis, M., Mevius, M., Michetti, A., Mikhailov, Yu, Miquel, R., Mizuk, R., Mohapatra, A., Moshkin, A., Moshous, B., Muresan, R., Nam, S., Negodaev, M., Négri, I., Nörenberg, M., Nowak, S., Núñez Pardo Vera, M. T., Oest, T., Oliveira, A., Ouchrif, M., Ould-Saada, F., Padilla, C., Pakhlov, P., Pavlenko, Yu, Peralta, D., Pernack, R., Perschke, T., Pestotnik, R., Petersen, B. Aa, Piccinini, M., Pleier, M. A., Poli, M., Popov, V., Pose, A., Pose, D., Potashnikova, I., Pugatch, V., Pylypchenko, Y., Pyrlik, J., Ramachandran, S., Ratnikov, F., Reeves, K., Rebing, D., Riechmann, K., Rieling, J., Rietz, M., Riu, I., Robmann, P., Rosen, J., Rothe, Ch, Ruckstuhl, W., Rusinov, V., Rybnikov, V., Ryzhikov, D., Saadi-Lüdemann, F., Samtleben, D., Sánchez, F., Sang, M., Saveliev, V., Sbrizzi, A., Schaller, S., Schlein, P., Schmelling, M., Schmidt, B., Schmidt, S., Schmidt-Parzefall, W., Schreiner, A., Schröder, H., Schultz, H. D., Schwanke, U., Schwartz, A. J., Schwarz, A. S., Schwenninger, B., Schwingenheuer, B., Schwitters, R., Sciacca, F., Semenov, S., Semprini-Cesari, N., Sexauer, E., Seybold, L., Shiu, J., Shuvalov, S., Siccama, I., Škrk, D., Sözüer, L., Soldatov, A., Solunin, S., Somov, A., Somov, S., Souvorov, V., Spahn, M., Spengler, J., Spighi, R., Spiridonov, A., Spratte, S., Stanovnik, A., Starič, M., Stdenis, R., Stegmann, C., Steinbeck, S., Steinkamp, O., Stieler, D., Straumann, U., Sun, F., Sun, H., Symalla, M., Takach, S., Tesch, N., Thurn, H., Tikhomirov, I., Maxim Titov, Trunk, U., Truöl, P., Tsakov, I., Uwer, U., Vagnoni, V., Eldik, C., Staa, R., Vassiliev, Yu, Villa, M., Vitale, A., Vukotic, I., Wagner, G., Wagner, W., Wahlberg, H., Walenta, A. H., Walter, M., Walter, T., Wang, J. J., Wang, Y. M., Wanke, R., Wegener, D., Werthenbach, U., Weyers, P. J., Wolters, H., Wurth, R., Wurz, A., Xella-Hansen, S., Yang, J., Zaitsev, Yu, Zavertyaev, M., Zech, G., Zeuner, T., Zhelezov, A., Zheng, Z., Zhu, Z., Zimmermann, R., Živko, T., Zoccoli, A., and Zweizig, J.

14. TRH-immunoreactivity in chronic pancreatitis

Author

Leonidas Duntas, Glasbrenner, B., Wolf, C., Pieramico, O., Buchler, M., and Malfertheiner, P.

Subjects
Adult, Blood Glucose, C-Peptide, Radioimmunoassay, Middle Aged, Fluoresceins, Glucagon, Thyroxine, Glucose, Pancreatitis, Chronic Disease, Humans, Insulin, Thyrotropin-Releasing Hormone, Aged
Abstract

Thyrotropin-releasing hormone (TRH) is abundantly present in the pancreas. We studied the circulating TRH-immunoreactivity (IR) in 27 patients with chronic pancreatitis (CP) and different degrees of exocrine pancreatic insufficiency (EPI), as well as in 23 normal subjects. Furthermore we examined the effect of oral administration of 100 g glucose on peripheral TRH-IR in normal subjects (n = 5) and in patients with severe exocrine insufficiency (SEI, n = 5). Basal TRH-IR plasma levels in the CP group (20.8 +/- 7 fmol/ml, mean +/- SD) were significantly lower (p0.005) as compared with the normal subjects (38 +/- 14). TRH-IR plasma levels in patients with CP and SEI (15.8 +/- 3) were significantly lower (p0.05) than in patients with normal pancreatic function (28.1 +/- 8), but were no different from those in patients with CP and moderate exocrine insufficiency (18.7 +/- 5). In normal controls TRH-IR rose 120-180 min after glucose ingestion from 33 +/- 5 to 64 +/- 20 fmol/ml, while no increase in TRH-IR levels was observed in patients with SEI. We conclude that circulating TRH-IR levels are mainly of pancreatic origin. Patients with SEI have very low peripheral TRH-IR, indicating that CP does indeed influence TRH-release.

15. Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS)

Author

Yi Miao, Zipeng Lu, Charles J. Yeo, Charles M. Vollmer, Carlos Fernandez-del Castillo, Paula Ghaneh, Christopher M. Halloran, Jörg Kleeff, Thijs de Rooij, Jens Werner, Massimo Falconi, Helmut Friess, Herbert J. Zeh, Jakob R. Izbicki, Jin He, Johanna Laukkarinen, Cees H. Dejong, Keith D. Lillemoe, Kevin Conlon, Kyoichi Takaori, Luca Gianotti, Marc G. Besselink, Marco Del Chiaro, Marco Montorsi, Masao Tanaka, Maximilian Bockhorn, Mustapha Adham, Attila Oláh, Roberto Salvia, Shailesh V. Shrikhande, Thilo Hackert, Tooru Shimosegawa, Amer H. Zureikat, Güralp O. Ceyhan, Yunpeng Peng, Guangfu Wang, Xumin Huang, Christos Dervenis, Claudio Bassi, John P. Neoptolemos, Markus W. Büchler, Anesthesiology, Surgery, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, Miao, Y, Lu, Z, Yeo, C, Vollmer, C, Fernandez-del Castillo, C, Ghaneh, P, Halloran, C, Kleeff, J, de Rooij, T, Werner, J, Falconi, M, Friess, H, Zeh, H, Izbicki, J, He, J, Laukkarinen, J, Dejong, C, Lillemoe, K, Conlon, K, Takaori, K, Gianotti, L, Besselink, M, Del Chiaro, M, Montorsi, M, Tanaka, M, Bockhorn, M, Adham, M, Olah, A, Salvia, R, Shrikhande, S, Hackert, T, Shimosegawa, T, Zureikat, A, Ceyhan, G, Peng, Y, Wang, G, Huang, X, Dervenis, C, Bassi, C, Neoptolemos, J, Buchler, M, RS: NUTRIM - R2 - Liver and digestive health, and MUMC+: MA Heelkunde (9)

Subjects
medicine.medical_specialty, REMNANT CLOSURE, medicine.medical_treatment, fistula formation, 030230 surgery, Anastomosis, Pancreatic surgery, law.invention, 03 medical and health sciences, Pancreatic Fistula, 0302 clinical medicine, Pancreatectomy, Postoperative Complications, Randomized controlled trial, law, medicine, Humans, Pancreas, business.industry, Expert consensus, POLYGLYCOLIC ACID FELT, stump closure, STAPLE LINE REINFORCEMENT, RANDOMIZED CONTROLLED-TRIAL, medicine.disease, soft coagulation, Surgery, hand-sewn closure, medicine.anatomical_structure, Pancreatic fistula, 030220 oncology & carcinogenesis, RISK-FACTORS, business, Distal pancreatectomy, TO-MUCOSA PANCREATICOGASTROSTOMY
Abstract

Background: The aim was to evaluate the various operative techniques and outcomes used to manage the pancreatic transection plane (or stump) during a left (distal) pancreatectomy and to develop expert consensus guidelines.Methods: Evidence-based, clinically relevant questions were discussed and then were circulated among members of the International Study Group of Pancreatic Surgery. After agreement on the questions and statements, voting in a 9-point Likert scale was used to gauge the level of objective support for each.Results: Studies using the International Study Group of Pancreatic Surgery definition of postoperative pancreatic fistula including 16 randomized trials were reviewed to generate a series of statements set into 14 domains. There was strong consensus in the following statements: there was no difference in the postoperative pancreatic fistula rate after left pancreatectomy between the handsewn and stapler techniques; a stapling technique could not be used in all cases of left pancreatectomy; the use of an energy-based tissue sealant or a chemical sealant device or combinations of these did not impact the postoperative pancreatic fistula rate; there was no difference in the postoperative pancreatic fistula rate between the open, laparoscopic, or robotic approaches; and there are 1 or more clinically important, patient-related risk factors associated with the postoperative pancreatic fistula rate. There was weak or conditional agreement on the use of prophylactic somatostatin analogs, stents, stump closure, stump anastomosis, and the role of abdominal drains.Conclusion: Areas of strong consensus suggests a change in clinical practice and priority setting. Eight domains with lower agreement will require novel approaches and large multicenter studies to determine future key areas of practice. (C) 2020 Elsevier Inc. All rights reserved.

Published
2019

16. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study

Author

Karsten Midtved, Matthias Büchler, L. Pallardó, Eric Thervet, Sergio Stefoni, Edward S. Cole, Sandra Cockfield, Francesco Paolo Schena, Michèle Kessler, Steve Chadban, Lorenzo Toselli, Helen Pilmore, César Agost Carreno, Stefoni S, Midtved K, Cole E, Thervet E, Cockfield S, Buchler M, Toselli L, Pallardo LM, Schena FP, Pilmore H, Kessler M, Chadban S, and Carreno CA.

Subjects
Adult, Graft Rejection, Male, medicine.medical_specialty, Randomization, Urinary system, Biopsy, Urology, Renal function, Azathioprine, Clinical endpoint, medicine, Humans, Aged, Transplantation, medicine.diagnostic_test, business.industry, Graft Survival, Middle Aged, Ciclosporin, Kidney Transplantation, Surgery, Therapeutic drug monitoring, Cyclosporine, Emulsions, Female, Drug Monitoring, business, Immunosuppressive Agents, medicine.drug
Abstract

Background. The clinical benefits of C 2 monitoring of cyclosporine microemulsion have been demonstrated, but C 2 targets in renal transplant recipients during the first year require validation. Methods. MO2ART was a prospective, multicenter study of renal transplant recipients managed by C 2 monitoring of cyclosporine microemulsion with steroids and mycophenolate mofetil or azathioprine. Patients were randomized on day 3 to two groups, which were managed from month 3 with higher or lower C 2 target ranges (months 4-6, 1,0001,200 ng/mL vs. 800-1,000 ng/mL; months 7-12, 800-1,000 ng/mL vs. 600-800 ng/mL, respectively). The primary endpoint was the glomerular filtration rate (GFR) at month 12. Results. A total of 296 patients were recruited, of whom 250 remained in the study at 3 months (higher-C 2 , n=131; lower-C 2 , n=119). GFR at 12 months did not differ between the higher- and lower-C 2 groups (65±17 mL/min vs. 66±14 mL/min). When patients were regrouped according to C 2 achieved by months 8 to 12, those with the lowest C 2 (

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results